Cancer prevention with rapamycin

Area of Science:

• Oncology
• Gerontology
• Pharmacology

Background:

• Cancer is a complex disease often associated with aging.
• Rapamycin (sirolimus) and rapalogs (everolimus) exhibit anti-cancer and anti-aging properties.
• These drugs target cellular pathways involved in proliferation and aging.

Purpose of the Study:

• To evaluate the cancer-preventive potential of rapamycin and its analogs.
• To explore the mechanisms by which rapamycin may delay cancer onset.
• To assess the relevance of preclinical findings to human cancer prevention.

Main Methods:

• Review of preclinical data from numerous murine cancer models.
• Analysis of clinical data from organ-transplant patients treated with rapamycin or everolimus.
• Consideration of rapamycin's effects on cell proliferation and aging.

Main Results:

• Rapamycin demonstrated robust and reproducible cancer prevention in diverse murine models.
• The drug effectively slowed tumor progression and delayed cancer onset in various settings.
• Clinical data in transplant patients suggest cancer-preventive effects.
• Rapamycin's mechanism involves targeting pre-cancerous cells and slowing organismal aging.

Conclusions:

• Rapamycin and its analogs show significant promise as cancer-preventive agents.
• The dual action of targeting pre-cancerous cells and slowing aging contributes to cancer delay.
• Further clinical investigation in high-risk populations, such as smokers, is warranted.